Tumor Biology

, Volume 37, Issue 5, pp 5857–5867 | Cite as

Irradiation induces glioblastoma cell senescence and senescence-associated secretory phenotype

  • Hee-Young Jeon
  • Jun-Kyum Kim
  • Seok Won Ham
  • Se-Yeong Oh
  • Jaebong Kim
  • Jae-Bong Park
  • Jae-Yong Lee
  • Sung-Chan Kim
  • Hyunggee Kim
Original Article

Abstract

Glioblastoma multiforme (GBM) is one of the most aggressive and fatal primary brain tumors in humans. The standard therapy for the treatment of GBM is surgical resection, followed by radiotherapy and/or chemotherapy. However, the frequency of tumor recurrence in GBM patients is very high, and the survival rate remains poor. Delineating the mechanisms of GBM recurrence is essential for therapeutic advances. Here, we demonstrate that irradiation rendered 17–20 % of GBM cells dead, but resulted in 60–80 % of GBM cells growth-arrested with increases in senescence markers, such as senescence-associated beta-galactosidase-positive cells, H3K9me3-positive cells, and p53-p21CIP1-positive cells. Moreover, irradiation induced expression of senescence-associated secretory phenotype (SASP) mRNAs and NFκB transcriptional activity in GBM cells. Strikingly, compared to injection of non-irradiated GBM cells into immune-deficient mice, the co-injection of irradiated and non-irradiated GBM cells resulted in faster growth of tumors with the histological features of human GBM. Taken together, our findings suggest that the increases in senescent cells and SASP in GBM cells after irradiation is likely one of main reasons for tumor recurrence in post-radiotherapy GBM patients.

Keywords

Glioblastoma multiforme Radiotherapy Recurrence Senescence Senescence-associated secretory phenotype 

Notes

Acknowledgments

We would like to thank all the members of the Cell Growth Regulation Laboratory for their helpful discussion and technical assistance. This work was supported by the National Nuclear Technology Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Science, ICT, and Future Planning (No. 2013M2A2A7042530 to H. Kim), and a research grant (to S.Y. Oh) funded by the Institute of Life Science and Natural Resources at Korea University.

Compliance with ethical standards

The study experiments were approved by the Animal Care Committee of the College of Life Sciences and Biotechnology, Korea University, according to government and institutional guidelines and regulations of Korea.

Conflicts of interest

None.

Supplementary material

13277_2015_4439_Fig7_ESM.gif (106 kb)
sFig. 1

Irradiation-induced GBM cell death was decreased by inhibition of NFκB signaling. FACS analysis revealed that early apoptotic cell populations (Annexin V-positive/PI-negative) of IκBα mutant-expressing GBM cells (U87MG and LN229) decreased compared to control counterpart GBM cells on Day 3 after irradiation with 20 Gy. There was no obvious difference on necrotic cell population (Annexin V-negative/PI-positive) in these cells. (GIF 105 kb)

13277_2015_4439_MOESM1_ESM.tif (14 mb)
High Resolution Image (TIF 14313 kb)
13277_2015_4439_Fig8_ESM.gif (134 kb)
sFig. 2

Irradiated GBM cells are not present in the tumor xenograft. a. FACS analysis showed cell populations expressing DsRed fluorescence in the mix of non-irradiated LN229 (1 × 10 ) and irradiated DsRed-expressing LN229 cells (2 × 10 ) before in vivo mouse co-injection. This experiment was set for a positive control. b. FACS analysis revealed that DsRed-positive cell populations were not present in tumors derived from the mix of non-irradiated LN229 and irradiated DsRed-expressing LN229 cells. Single cells dissociated from tumors derived from non-irradiated LN229 cells alone were used as a negative control. (GIF 133 kb)

13277_2015_4439_MOESM2_ESM.tif (17.2 mb)
High Resolution Image (TIF 17639 kb)

References

  1. 1.
    Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.CrossRefPubMedGoogle Scholar
  2. 2.
    Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.CrossRefPubMedGoogle Scholar
  3. 3.
    Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010;16:2443–9.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Liang BC, Thornton Jr AF, Sandler HM, Greenberg HS. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg. 1991;75:559–63.CrossRefPubMedGoogle Scholar
  5. 5.
    Sneed PK, Gutin PH, Larson DA, Malec MK, Phillips TL, Prados MD, et al. Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys. 1994;29:719–27.CrossRefPubMedGoogle Scholar
  6. 6.
    Chang JE, Khuntia D, Robins HI, Mehta MP. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol. 2007;894–902:7–15.Google Scholar
  7. 7.
    Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol. 2013;10:14–26.CrossRefPubMedGoogle Scholar
  8. 8.
    Persano L, Rampazzo E, Basso G, Viola G. Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting. Biochem Pharmacol. 2013;85:612–22.CrossRefPubMedGoogle Scholar
  9. 9.
    Mitchell JB, Choudhuri R, Fabre K, Sowers AL, Citrin D, Zabludoff SD, et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res. 2010;16:2076–84.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Bernhard EJ, Maity A, Muschel RJ, McKenna WG. Effects of ionizing radiation on cell cycle progression. Radiat Environ Biophys. 1995;34:79–83.CrossRefPubMedGoogle Scholar
  11. 11.
    Maity A, McKenna WG, Muschel RJ. The molecular basis for cell cycle delays following ionizing radiation: a review. Radiother Oncol. 1994;31:1–13.CrossRefPubMedGoogle Scholar
  12. 12.
    Campisi J, di Fagagna FA. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8:729–40.CrossRefPubMedGoogle Scholar
  13. 13.
    Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res. 2003;63:2705–15.PubMedGoogle Scholar
  14. 14.
    Bravata V, Minafra L, Russo G, Forte GI, Cammarata FP, Ripamonti M, et al. High-dose ionizing radiation regulates gene expression changes in the MCF7 breast cancer cell line. Anticancer Res. 2015;35:2577–91.PubMedGoogle Scholar
  15. 15.
    Ye C, Zhang X, Wan J, Chang L, Hu W, Bing Z, et al. Radiation-induced cellular senescence results from a slippage of long-term G2 arrested cells into G1 phase. Cell Cycle. 2013;12:1424–32.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hornsby PJ. Senescence as an anticancer mechanism. J Clin Oncol. 2007;25:1852–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Wu C-H, van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A. 2007;104:13028–33.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Cerella C, Grandjenette C, Dicato M, Diederich M. Roles of apoptosis and cellular senescence in cancer and aging. Curr Drug Targets. 2015.Google Scholar
  19. 19.
    Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol. 2013;15:978–90.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011;192:547–56.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Han NK, Kim BC, Lee HC, Lee YJ, Park MJ, Chi SG, et al. Secretome analysis of ionizing radiation‐induced senescent cancer cells reveals that secreted rkip plays a critical role in neighboring cell migration. Proteomics. 2012;12:2822–32.CrossRefPubMedGoogle Scholar
  22. 22.
    Acosta JC, O’Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell. 2008;133:1006–18.CrossRefPubMedGoogle Scholar
  23. 23.
    Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:2853–68.CrossRefPubMedGoogle Scholar
  24. 24.
    Liao EC, Hsu YT, Chuah QY, Lee YJ, Hu JY, Huang TC, et al. Radiation induces senescence and a bystander effect through metabolic alterations. Cell Death Dis. 2014;5, e1255.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mosieniak G, Strzeszewska A. The role of cellular senescence in carcinogenesis and antitumor therapy. Postepy Biochem. 2014;60:194–206.PubMedGoogle Scholar
  26. 26.
    Petit V, Massonnet G, Maciorowski Z, Touhami J, Thuleau A, Nemati F, et al. Optimization of tumor xenograft dissociation for the profiling of cell surface markers and nutrient transporters. Lab Investig. 2013;93:611–21.CrossRefPubMedGoogle Scholar
  27. 27.
    Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–10.CrossRefPubMedGoogle Scholar
  28. 28.
    Pyrko P, Soriano N, Kardosh A, Liu Y-T, Uddin J, Petasis NA, et al. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer. 2006;5:19.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden JE, et al. Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev. 2011;25:2125–36.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Bartkova J, Hořejší Z, Koed K, Krämer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–70.CrossRefPubMedGoogle Scholar
  31. 31.
    Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436:720–4.CrossRefPubMedGoogle Scholar
  32. 32.
    Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A. 2001;98:12072–7.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.CrossRefPubMedGoogle Scholar
  34. 34.
    Yang I, Aghi MK. New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol. 2009;6:648–57.CrossRefPubMedGoogle Scholar
  35. 35.
    Liu SC, Alomran R, Chernikova SB, Lartey F, Stafford J, Jang T, et al. Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats. Neuro Oncol. 2014;16:21–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Qian B-Z, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475:222–5.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Lu X, Kang Y. Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem. 2009;284:29087–96.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Kuo PL, Shen KH, Hung SH, Hsu YL. CXCL1/GROalpha increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-kappaB/HDAC1 epigenetic regulation. Carcinogenesis. 2012;33:2477–87.CrossRefPubMedGoogle Scholar
  39. 39.
    Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301–10.CrossRefPubMedGoogle Scholar
  40. 40.
    Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ. 2006;13:738–47.CrossRefPubMedGoogle Scholar
  41. 41.
    Atkinson GP, Nozell SE, Benveniste ET. NF-kappaB and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother. 2010;10:575–86.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Hee-Young Jeon
    • 1
    • 2
  • Jun-Kyum Kim
    • 1
    • 2
  • Seok Won Ham
    • 1
  • Se-Yeong Oh
    • 3
  • Jaebong Kim
    • 4
  • Jae-Bong Park
    • 4
  • Jae-Yong Lee
    • 4
  • Sung-Chan Kim
    • 4
  • Hyunggee Kim
    • 1
    • 2
  1. 1.Department of Biotechnology, School of Life Sciences and BiotechnologyKorea UniversitySeoulSouth Korea
  2. 2.Institute of Animal Molecular BiotechnologyKorea UniversitySeoulSouth Korea
  3. 3.Institute of Life Science and Natural ResourcesKorea UniversitySeoulSouth Korea
  4. 4.Department of Biochemistry, Institute of Cell Differentiation and Aging, College of MedicineHallym UniversityChuncheonSouth Korea

Personalised recommendations